Anti-parathyroid treatment effectiveness and persistence in incident haemodialysis patients with secondary hyperparathyroidism

Estadísticas

Original article

Efectividad y persistencia de los tratamientos del hiperparatiroidismo secundario en pacientes incidentes en hemodialisis

Angel Luis Martín de Franciscoa,⿿

Autor para correspondencia

angelmartindefrancisco@gmail.com

Corresponding author.

, Iain Andrew Gillespieb, Ioanna Gionic, Jürgen Floeged, Florian Kronenberge, Daniele Marcellif, David Collins. Wheelerg, Marc Froissarth, Tilman Bernhard. Druekei, on behalf of the ARO Steering Committee Cllaborators ⿿

a Servicio de Nefrología, Hospital Universitario Valdecilla, Universidad de Cantabria, Santander, Spain

b Center for Observational Research (CfOR), Amgen Ltd, Uxbridge, United Kingdom

c On behalf of Amgen Ltd, United Kingdom

d Nephrology, RWTH University of Aachen, Aachen, Germany

e Division of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Medical University of Innsbruck, Innsbruck, Austria

f EMEALA Medical Board, Fresenius Medical Care, Bad Homburg, Germany

g Center for Nephrology, Division of Medicine, University College London, United Kingdom

h International Development Nephrology, Amgen Europe GmbH, Zug, Switzerland

i Inserm U 1088, UFR Médecine/Pharmacie, Université de Picardie, Amiens, France

Leído

13000

Veces
se ha leído el artículo

3576

Total PDF

9424

Total HTML

Compartir estadísticas

Información del artículo

ISSN: 02116995
Idioma original: Inglés

DOI:10.1016/j.nefro.2015.10.006

Datos actualizados diariamente

año/Mes	Html	Pdf	Total

2025 11	71	18	89
2025 10	105	47	152
2025 9	89	57	146
2025 8	83	56	139
2025 7	174	26	200
2025 6	134	31	165
2025 5	106	41	147
2025 4	79	19	98
2025 3	116	59	175
2025 2	83	41	124
2025 1	59	37	96
2024 12	49	31	80
2024 11	68	50	118
2024 10	49	40	89
2024 9	46	25	71
2024 8	70	60	130
2024 7	44	24	68
2024 6	67	48	115
2024 5	52	39	91
2024 4	58	63	121
2024 3	55	43	98
2024 2	52	52	104
2024 1	56	30	86
2023 12	57	27	84
2023 11	61	35	96
2023 10	72	25	97
2023 9	40	23	63
2023 8	39	24	63
2023 7	49	29	78
2023 6	40	18	58
2023 5	36	30	66
2023 4	31	19	50
2023 3	40	29	69
2023 2	44	22	66
2022 1	37	29	66
2022 12	64	47	111
2022 11	62	52	114
2022 10	64	47	111
2022 9	37	36	73
2022 8	46	52	98
2022 7	39	61	100
2022 6	41	61	102
2022 5	31	40	71
2022 4	61	66	127
2022 3	39	43	82
2022 2	44	50	94
2021 1	48	34	82
2021 12	49	47	96
2021 11	46	46	92
2021 10	59	42	101
2021 9	45	41	86
2021 8	46	55	101
2021 7	39	45	84
2021 6	73	48	121
2021 5	81	37	118
2021 4	126	85	211
2021 3	80	44	124
2021 2	69	19	88
2020 1	48	30	78
2020 12	41	22	63
2020 11	55	24	79
2020 10	48	28	76
2020 9	32	26	58
2020 8	48	22	70
2020 7	38	16	54
2020 6	53	19	72
2020 5	67	36	103
2020 4	38	24	62
2020 3	58	29	87
2020 2	42	41	83
2020 1	59	39	98
2019 12	50	24	74
2019 11	36	25	61
2019 10	39	34	73
2019 9	41	30	71
2019 8	37	24	61
2019 7	26	28	54
2019 6	43	33	76
2019 5	26	40	66
2019 4	90	52	142
2019 3	42	44	86
2019 2	44	26	70
2019 1	38	41	79
2018 12	149	52	201
2018 11	234	17	251
2018 10	126	12	138
2018 9	101	10	111
2018 8	87	16	103
2018 7	59	10	69
2018 6	76	17	93
2018 5	62	14	76
2018 4	157	14	171
2018 3	126	16	142
2018 2	164	13	177
2018 1	100	10	110
2017 12	201	16	217
2017 11	75	22	97
2017 10	84	14	98
2017 9	61	17	78
2017 8	59	16	75
2017 7	71	12	83
2017 6	74	15	89
2017 5	114	16	130
2017 4	86	14	100
2017 3	58	20	78
2017 2	142	9	151
2016 1	61	12	73
2016 12	96	11	107
2016 11	131	20	151
2016 10	206	18	224
2016 9	245	8	253
2016 8	241	15	256
2016 7	228	18	246
2016 6	197	0	197
2016 5	262	0	262
2016 4	238	0	238
2016 3	137	0	137
2016 2	64	0	64
2015 1	58	0	58
2015 12	55	0	55

Mostrar todo

Indexada en:

Síguenos:

Estadísticas

Indexada en:

Síguenos:

Estadísticas

Suscríbase a la newsletter